



--- EMBARGOED UNTIL 11:30 AM ET, TUESDAY, MAY 8, 2007 ---

Former President Clinton Announces Breakthrough on “Next Generation” One-Pill, Once-Daily AIDS Treatment: \$1 Per Day Price Reduces Cost By 45% or More in Developing Countries

Cipla and Matrix Will Offer New Prices for 14 Drug Formulations across 65 Countries

Commitment to Uniform Pricing Leads to Major Price Reductions for Middle Income Countries

UNITAID, Clinton Foundation Partner in \$100 Million Effort to Provide “Second Line” Drugs; Initial Price Reduction of 25% in Low Income, 50% in Middle Income Countries

New York—Former President Bill Clinton announced today new agreements with Cipla and Matrix that lower the price of AIDS treatment, achieved in partnership with UNITAID.

Citing the importance of keeping AIDS treatment affordable as patients increasingly turn to newer drugs for effective first and second-line treatment, President Clinton highlighted the \$339 per patient annual price of the once-daily “gold standard” treatment combining the drugs tenofovir, lamivudine and efavirenz. The equivalent product in the U.S., launched in July 2006, offers greater convenience, fewer side effects, and improved treatment outcomes in comparison to the regimen used most commonly in developing countries. The price represents a 45% reduction from the current rate available to low income countries, including those in sub-Saharan Africa, and a 67% reduction from the price available to many middle income countries.

Commitments from Cipla and Matrix Laboratories – both of which have been partners of the Clinton Foundation since 2003 – will lower the price of seven drugs in 14 formulations. The reduced prices will be available to all members of the Foundation’s Procurement Consortium, which currently includes 65 developing countries in Africa, Asia, Latin America and the Caribbean.

The agreements include reduced prices for second-line drugs, which sustain the efficacy of treatment for patients who develop drug resistance to first-line therapy. Compared to current market prices, the new prices will generate an average savings of 25% in low-income countries and 50% in middle-income countries. The price reductions have been made possible by UNITAID, the international drug purchase facility established in 2006 by France, Brazil, Chile, Norway and the UK. UNITAID will provide the Clinton Foundation HIV/AIDS Initiative (CHAI) with more than \$100 million to buy second-line medicines for 27 countries through 2008.

“I applaud Cipla and Matrix for their commitment to lowering prices for the new drugs at the forefront of the fight against AIDS, and I thank UNITAID for the new funds that have made these prices possible,” said President Clinton. “There are two million people on treatment in developing countries today and another five million who need access. These new agreements allow us to meet their needs with the best medicines that science can offer while keeping the drugs affordable.”

French Foreign Minister Philippe Douste-Blazy, chairman of the UNITAID board, added, “Every person living with HIV deserves access to the most effective medicines, and UNITAID aims to ensure that these are affordable for all developing countries. I am pleased that our partnership with President Clinton is lowering the price of second-line treatment, and that the new prices will be available to low and middle income countries alike.”

In partnership with UNITAID, CHAI issued an open invitation in March 2007 to 15 manufacturers for proposals to supply second-line drugs later this year. Cipla and Matrix agreed to price their drugs on a “cost-plus” basis and collaborated with CHAI to lower production costs, in part by securing lower prices for key raw materials and by addressing major chemistry challenges. CHAI will use UNITAID funds to purchase these reduced-priced medicines, guaranteeing purchase volumes. Additional suppliers selected to participate in the program for 2007 include Abbott, Aurobindo, Bristol Myers Squibb, Gilead Sciences, Ranbaxy, and Aspen Pharmacare and IDS Group, as designated distributors of Gilead in Africa and Asia.

CHAI will facilitate a similar process of competitive bidding and supplier selection for the 2008 portion of the program, and expects to announce further price reductions by the end of the year.

CHAI is committed to ensuring that its agreements offer high-quality products at sustainable prices. The products that will be supplied under CHAI’s partnership with UNITAID meet the quality assurance standards of the Global Fund to Fight AIDS, Tuberculosis and Malaria, which prioritize approval by the World Health Organization, the U.S. Food and Drug Administration or another stringent regulatory authority. These products have either already been approved by the WHO and/or FDA or have been submitted for review with data establishing bioequivalence, based on tests by research laboratories that have been successfully audited by the WHO and/or FDA. Products purchased with UNITAID funds will also be subject to routine quality control testing. Additional products included in today’s announcement have either been approved by the WHO/FDA or will be submitted for review no later than July.

About the Clinton Foundation HIV/AIDS Initiative

Since 2002, the Clinton Foundation HIV/AIDS Initiative has assisted countries in implementing large-scale, integrated care, treatment and prevention programs. CHAI partners with 25 countries in Africa, the Caribbean and Asia. Individual governments take the lead, and the Foundation provides technical assistance, mobilizes human and financial resources, and facilitates the sharing of best practices across projects. CHAI also provides access to reduced prices for HIV/AIDS drugs and diagnostics to a total of 65 countries, which together represent more than 90 percent of people living with HIV/AIDS in developing countries.

About UNITAID

Launched in 2006, UNITAID is an international drug purchase facility that is based on a stable, predictable and “innovative” form of funding – an airline ticket levy – used to fight HIV/AIDS, tuberculosis and malaria. In total, 34 countries have either joined or committed themselves to join UNITAID as donors. The funding for 2007 will total \$300 million, and is expected to exceed \$500 million in 2009. UNITAID relies on strong partnerships – e.g, with the WHO and Global Fund, with UNICEF for the supply of new malaria treatments, with the Clinton Foundation for the supply

of antiretrovirals, and with the Stop TB Partnership for the supply of pediatric TB medicines – to make quality drugs affordable and available in the poorest countries. UNITAID has already begun to show results, with treatment in more than 50 countries and initial reductions in drug prices.

CONTACT INFORMATION FOR PRESS INQUIRIES

For the Clinton Foundation – New York Office: +1 212 348 0360

For UNITAID – Mr Paulo Meireles: +41 22 791 2325

For Cipla – Mr. Shailesh Pednekar: +91 98 2060 9408

For Matrix – Mr. S. Srinivasan: +91 98 4854 3210 or Mr. Patrick Fitzgerald: +1 724 454 6113